Condensed Balance Sheets [Abstract] Total current assets Property and equipment, gross Net property and equipment Total long-term assets Total assets Total current liabilities Total long-term liabilities Total liabilities Total stockholders’ equity Balance Balance Total liabilities and stockholders’ equity Condensed Statements of Operations and Comprehensive Loss [Abstract] Total operating expenses Loss from operations Total other income (expense), net Total other income (expense), net Loss before income taxes Loss before income taxes Net loss Net loss Net income Condensed Statements of Stockholders’ Equity [Abstract] Balance (in Shares) Balance (in Shares) Common stock, issued (in Shares) Common stock, issued (in shares) Treasury stock, common shares (in Shares) Treasury stock, common shares (in Shares) Treasury stock, common shares (in Shares) Class of Warrant or Right [Axis] Equity Components [Axis] Condensed Statements of Cash Flows [Abstract] Net cash used in operating activities Net cash used in investing activities Net cash provided by financing activities Net change in cash and cash equivalents Beginning of period End of period Debt Instrument [Axis] Organization, Nature of Business, and Liquidity [Abstract] Fair Value of Financial Instruments [Abstract] Balance Balance Liability Class [Axis] Measurement Input Type [Axis] Statistical Measurement [Axis] Cash and Cash Equivalents [Abstract] Inventories [Abstract] Inventory Inventory Accrued Expenses [Abstract] Accrued expenses Accrued expenses Revenue Recognition [Abstract] Geographical [Axis] Commitments and Contingencies [Abstract] Convertible Notes with Warrants [Abstract] Long-Term Debt, Type [Axis] Convertible Notes Payable Stockholders’ Equity [Abstract] Equity Incentive Plans and Warrants [Abstract] Number of options, Beginning balance (in Shares) Number of options, Ending balance (in Shares) Weighted average exercise price, Beginning balance (in Dollars per share) Weighted average exercise price, Ending balance (in Dollars per share) Aggregate intrinsic value, outstanding (in Dollars) Aggregate intrinsic value, outstanding (in Dollars) Employee Stock Ownership Plan (ESOP) Name [Axis] Grantee Status [Axis] Number of RSUs, Beginning balance (in Shares) Number of RSUs, Ending balance (in Shares) Weighted average grant date fair value, Beginning balance (in Dollars per share) Weighted average grant date fair value, Ending balance (in Dollars per share) Award Type [Axis] Related‑Party Transactions [Abstract] Net Loss per Share Attributable to Common Stockholders [Abstract] Income Taxes [Abstract] Segment Reporting [Abstract] Total research and development expense Research and development Segments [Axis] Other Income (expense), net [Abstract] Subsequent Events [Abstract] Document Type Document Quarterly Report Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Amendment Flag Document Fiscal Period Focus Current Fiscal Year End Date Current assets: Cash and cash equivalents Accounts receivable, net Prepaid and other current assets Property and equipment, at cost: Leasehold improvements Office equipment Furniture and fixtures Machinery and equipment Construction in progress Long-term assets: Lease right-of-use assets, net Intangible assets, net of accumulated amortization Other long-term assets Current liabilities: Accounts payable Clinical holdback – current portion Operating lease liabilities – current portion Long-term liabilities: Clinical holdback – long-term portion Convertible notes payable, net Conversion option liability Warrants liabilities Operating lease liabilities – long-term portion Commitments and contingencies Stockholders' equity: Common stock, $0.001 par, 200,000,000 authorized, 3,029,829 shares issued and 3,023,967 outstanding as of June 30, 2026; and 2,986,116 shares issued and 2,980,254 outstanding as of December 31, 2025 Common stock, par value (in Dollars per share) Common stock, par value Common stock, authorized (in Shares) Common stock, outstanding (in Shares) Warrants Additional paid-in capital Accumulated deficit Sales Cost of sales (excluding depreciation expense) Operating expenses: Sales and marketing Sales and marketing expense General and administrative General and administrative expense Depreciation and amortization Depreciation and amortization expense Other income (expense): Interest income Other expense Income tax expense (benefit) Net loss attributable to common stockholders, basic Net loss attributable to common stockholders, diluted Basic loss per share (in Dollars per share) Loss per share, basic (in Dollars per share) Diluted loss per share (in Dollars per share) Loss per share, diluted (in Dollars per share) Weighted-average common shares outstanding, basic (in Shares) Weighted average common shares outstanding, basic (in Shares) Weighted-average common shares outstanding, diluted (in Shares) Weighted average common shares outstanding, diluted (in Shares) Conversion option liability and warrants liabilities reclassification Issuance of common stock in connection with ESPP Issuance of common stock in connection with ESPP (in Shares) Share-based compensation expense Issuance of common stock in connection with at-the-market offering, net of issuance costs Issuance of common stock in connection with at-the-market offering, net of issuance costs (in Shares) Issuance of common shares in payment of 2023 convertible note interest, including related parties Payment of convertible notes interest Issuance of common shares in payment of 2023 convertible note interest, including related parties (in Shares) Payment of convertible notes interest (in Shares) Conversion of 2025 convertible notes into common stock Conversion of convertible note Conversion of 2025 convertible notes into common stock (in Shares) Issuance of common stock in connection with financing, net of issuance costs Issuance of common stock in connection with financing, net of issuance costs (in Shares) Issuance of warrants in connection with June 2025 financing Warrants value Expiration of warrant Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Amortization Change in fair value of conversion option liability Change in fair value of conversion option liability Change in fair value of Conversion Option Liability Change in fair value of warrants liabilities Change in fair value of warrants liabilities Change in fair value other than modification Change in fair value of Warrants liabilities Amortization of right-of-use assets Share-based compensation expense Changes in operating assets and liabilities: Accounts payable Accrued expenses Lease liabilities Other liabilities Cash flows from investing activities: Cash flows from financing activities: Proceeds from the issuance of common stock in June 2025 financing Proceeds from at-the-market sales of common stock Proceeds from At-The-Market Sales of Common Stock Proceeds from common stock issued through ESPP Cash and cash equivalents: Supplemental cash flow information